KURA Stock Price, Kura Oncology Inc Quote, Chart

Market Summary

USD20.63-0.08

Market Closed

-0.39%

KURA Stock Price

View Fullscreen

KURA RSI Chart

KURA Valuation

Market Cap

1.6B

Price/Earnings (Trailing)

-9.35

Price/Sales (Trailing)

106.75

Price/Free Cashflow

-11.39

KURA Price/Sales (Trailing)

KURA Profitability

Return on Equity

-33.28%

Return on Assets

-30.35%

Free Cashflow Yield

-8.78%

KURA Fundamentals

KURA Revenue

Revenue (TTM)

14.7M

Rev. Growth (Yr)

86.12%

Rev. Growth (Qtr)

24.69%

KURA Earnings

Earnings (TTM)

-168.1M

Earnings Growth (Yr)

-45.37%

Earnings Growth (Qtr)

-15.75%

Breaking Down KURA Revenue

Last 7 days

-1.8%

Last 30 days

5.9%

Last 90 days

5.9%

Trailing 12 Months

68.6%

How does KURA drawdown profile look like?

KURA Financial Health

Current Ratio

16.67

Debt/Equity

0.02

Debt/Cashflow

-14.7

KURA Investor Care

Shares Dilution (1Y)

11.31%

Diluted EPS (TTM)

-2.17

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	6.8M	9.4M	0	14.7M
2022	1.2M	1.5M	2.3M	4.3M
2021	2.0M	0	1.5M	1.2M
2020	5.0M	4.8M	4.0M	2.8M
2019	3.7M	4.1M	4.5M	4.9M
2018	1.0M	1.5M	2.4M	3.2M
2017	780.0K	709.0K	711.0K	784.5K
2016	1.2M	1.1M	990.0K	885.0K
2015	0	0	1.2M	1.2M
2014	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Kura Oncology Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jan 30, 2024	dale stephen	sold	-103,980	21.5502	-4,825	chief medical officer
Jan 29, 2024	dale stephen	sold	-127,416	17.8005	-7,158	chief medical officer
Jan 29, 2024	bair teresa brophy	sold	-36,544	17.8005	-2,053	chief legal officer
Jan 29, 2024	doyle thomas james	sold	-41,261	17.8005	-2,318	svp, finance & accounting
Jan 29, 2024	ford kathleen	sold	-26,629	17.8005	-1,496	chief operating officer
Jan 24, 2024	wilson troy edward	sold	-1,841,980	20.23	-91,052	president and ceo
Jan 24, 2024	wilson troy edward	acquired	550,594	6.04703	91,052	president and ceo
Jan 02, 2024	doyle thomas james	acquired	-	-	21,250	svp, finance & accounting
Jan 02, 2024	bair teresa brophy	acquired	-	-	46,250	chief legal officer
Jan 02, 2024	powl brian t.	acquired	-	-	15,000	chief commercial officer

Which funds bought or sold KURA recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 10, 2024	Campbell & CO Investment Adviser LLC	new	-	284,521	284,521	0.03%
May 10, 2024	GROUP ONE TRADING, L.P.	added	812	41,975	45,326	-%
May 10, 2024	PNC Financial Services Group, Inc.	unchanged	-	42.00	128	-%
May 10, 2024	BlackRock Inc.	reduced	-5.69	41,964,500	147,164,000	-%
May 10, 2024	WELLS FARGO & COMPANY/MN	added	11.26	220,610	559,849	-%
May 10, 2024	Pacer Advisors, Inc.	new	-	30,950	30,950	-%
May 10, 2024	OSAIC HOLDINGS, INC.	new	-	42.00	42.00	-%
May 10, 2024	JPMORGAN CHASE & CO	reduced	-8.16	2,464,040	9,265,670	-%
May 10, 2024	Covestor Ltd	reduced	-40.00	-	-	-%
May 10, 2024	DIMENSIONAL FUND ADVISORS LP	reduced	-31.89	297,135	29,082,100	0.01%

Are Funds Buying or Selling KURA?

Are funds buying KURA calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own KURA

No. of Funds

Unveiling Kura Oncology Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
May 02, 2024	paradigm biocapital advisors lp	5.1%	3,861,318	SC 13G
Feb 14, 2024	ecor1 capital, llc	9.99%	7,598,797	SC 13G/A
Feb 14, 2024	biotechnology value fund l p	5.1%	3,801,949	SC 13G/A
Feb 13, 2024	suvretta capital management, llc	9.99%	7,472,343	SC 13G/A
Feb 13, 2024	vanguard group inc	5.44%	4,037,691	SC 13G/A
Feb 12, 2024	flynn james e	7.15%	5,312,733	SC 13G/A
Jan 24, 2024	blackrock inc.	9.8%	7,315,647	SC 13G/A
Jan 23, 2024	state street corp	3.93%	2,921,810	SC 13G/A
Sep 21, 2023	flynn james e	5.89%	4,374,044	SC 13G
Feb 14, 2023	deep track capital, lp	0%	0	SC 13G/A

Recent SEC filings of Kura Oncology Inc

View All Filings

Date Filed	Form Type	Document
May 02, 2024	10-Q	Quarterly Report
May 02, 2024	8-K	Current Report
May 02, 2024	SC 13G	Major Ownership Report
Apr 18, 2024	ARS	ARS
Apr 12, 2024	DEF 14A	DEF 14A
Apr 12, 2024	DEFA14A	DEFA14A
Feb 29, 2024	UPLOAD	UPLOAD
Feb 27, 2024	8-K	Current Report
Feb 27, 2024	10-K	Annual Report
Feb 27, 2024	S-8	Employee Benefits Plan

Peers (Alternatives to Kura Oncology Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	48.2B	6.8B	19.54%	-2.80%	-8.07	7.03	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	19.0B	2.0B	0.98%	-26.98%	-57.12	9.47	75.20%	68.82%
BMRN	15.3B	2.5B	-12.72%	-14.31%	74.39	6.18	13.74%	186.89%
INCY	12.9B	3.8B	6.98%	-11.75%	17.35	3.43	8.58%	129.81%
MID-CAP
BBIO	5.3B	107.9M	6.22%	110.41%	-9.76	48.09	54.84%	-28.31%
APLS	5.2B	524.1M	-16.95%	-51.10%	-12.51	9.96	394.93%	39.61%
AXSM	3.6B	251.0M	9.36%	-4.29%	-12.12	14.31	73.58%	-86.73%
ARWR	2.7B	240.7M	-10.69%	-43.90%	-5.82	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-11.38%	-29.25%	-1.5K	3.08	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	6.64%	20.67%	29.44	4.66	60.38%	-34.49%
NVAX	1.8B	996.6M	206.31%	55.15%	-4.62	1.85	-26.66%	65.49%
CRBP	458.7M	881.7K	5.07%	336.18%	-13.59	481.06	-77.61%	33.36%
INO	294.6M	4.9M	3.08%	29.79%	-2.36	60.54	-54.97%	48.23%
IBIO	15.6M	2.1M	-10.40%	79.21%	-0.67	7.61	-13.45%	69.54%

Kura Oncology Inc News

Latest updates

Kura Oncology Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3
Revenue	24.7%	5,325	4,271	3,216	2,861	2,271	1,090	564	329	295	311	310	331	571	818	1,119	1,471	1,396	1,022	1,030	1,048	1,047
Operating Expenses	16.4%	54,452	46,762	40,003	36,566	35,156	36,594	35,333	32,782	33,038	33,677	30,896	26,332	24,194	21,173	20,200	18,963	17,674	15,891	14,951	16,634	15,982
S&GA Expenses	-100.0%	-	14,229	11,821	11,374	12,488	11,621	11,075	11,869	12,082	11,310	10,572	8,808	7,593	7,476	7,625	5,499	5,134	4,451	4,569	-	-
R&D Expenses	11.5%	36,268	32,533	28,182	25,192	22,668	24,973	24,258	20,913	20,956	22,367	20,324	17,524	16,601	13,697	12,575	13,464	12,540	11,440	10,382	-	-
Interest Expenses	1.0%	398	394	387	364	-	-	-	-	-	-	108	144	146	144	144	142	145	148	145	193	252
Net Income	-15.8%	-49,525	-42,786	-37,174	-34,069	-33,114	-35,504	-34,769	-32,453	-32,743	-33,366	-30,694	-26,159	-23,769	-20,487	-19,210	-17,865	-16,392	-14,943	-13,940	-16,097	-15,007
Net Income Margin	-10.1%	-11.42*	-10.37*	-14.82*	-20.26*	-31.93*	-59.47*	-88.95*	-106.20*	-104.67*	-81.37*	-	-	-	-	-	-	-	-	-	-	-
Free Cashflow	-42.5%	-48,928	-34,324	-25,713	-35,908	-26,542	-21,391	-30,525	-32,230	-23,468	-25,317	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	23.4%	554	449	474	495	426	456	448	471	499	534	561	585	620	647	340	353	226	242	255	266	170
Current Assets	24.4%	538	432	460	486	416	446	436	460	487	522	549	574	611	637	329	342	221	240	253	264	168
Cash Equivalents	11.2%	42.00	37.00	29.00	49.00	27.00	52.00	91.00	39.00	34.00	91.00	39.00	39.00	111	325	77.00	135	34.00	26.00	55.00	122	18.00
Net PPE	-8.1%	2.00	2.00	2.00	2.00	2.00	3.00	3.00	3.00	3.00	3.00	3.00	2.00	2.00	2.00	2.00	2.00	1.00	0.00	-	-	-
Liabilities	-5.5%	49.00	52.00	44.00	35.00	31.00	36.00	28.00	22.00	22.00	27.00	27.00	26.00	34.00	36.00	33.00	31.00	23.00	23.00	21.00	19.00	20.00
Current Liabilities	-8.5%	32.00	35.00	28.00	24.00	19.00	24.00	25.00	18.00	18.00	22.00	22.00	21.00	25.00	26.00	22.00	19.00	15.00	16.00	13.00	11.00	12.00
Long Term Debt	0.5%	9.00	9.00	9.00	9.00	9.00	9.00	-	-	-	-	-	-	4.00	4.00	5.00	6.00	7.00	7.00	8.00	8.00	8.00
LT Debt, Current	-	-	-	-	-	-	-	-	-	-	-	-	-	3.00	3.00	3.00	2.00	1.00	0.00	-	-	-
LT Debt, Non Current	-100.0%	-	9.00	9.00	9.00	9.00	9.00	-	-	-	-	-	-	4.00	4.00	5.00	6.00	7.00	7.00	8.00	8.00	8.00
Shareholder's Equity	27.1%	505	397	430	460	395	420	420	449	476	507	534	559	586	611	306	322	203	219	234	247	150
Retained Earnings	-6.9%	-770	-721	-678	-640	-602	-568	-535	-500	-465	-432	-400	-366	-333	-302	-276	-252	-232	-212	-195	-178	-163
Additional Paid-In Capital	14.0%	1,277	1,120	1,112	1,105	1,004	997	965	957	948	941	934	926	919	913	583	574	435	431	428	425	313
Shares Outstanding	2.5%	76.00	74.00	74.00	74.00	68.00	68.00	67.00	67.00	67.00	66.00	66.00	66.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	777	-	-	-	1,200	-	-	-	1,300	-	-	-	878	-	-	-	822	-

Cashflow (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Cashflow (Quarterly)																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-42.4%	-48.84	-34.31	-29.03	-25.62	-35.87	-26.53	-21.01	-30.34	-32.18	-23.37	-24.59	-28.07	-28.52	-18.31	-16.97	-14.73	-19.82	-13.93	-12.14	-14.43	-14.25
Share Based Compensation	18.8%	9.00	7.00	7.00	7.00	7.00	7.00	6.00	7.00	7.00	6.00	6.00	6.00	5.00	4.00	3.00	3.00	3.00	2.00	2.00	2.00	2.00
Cashflow From Investing	-325.9%	-95.34	42.00	9.00	-46.33	11.00	-47.32	72.00	33.00	-24.96	74.00	23.00	-37.22	-186	-60.19	-45.52	-21.69	27.00	-15.26	-55.75	9.00	16.00
Cashflow From Financing	21371.6%	148	1.00	0.00	-	-	35.00	1.00	3.00	0.00	1.00	2.00	-6.57	0.00	327	5.00	137	0.00	1.00	1.00	110	0.00

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

KURA Income Statement

2024-03-31

Condensed Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating Expenses:
Research and development	$ 36,268	$ 25,192
General and administrative	18,184	11,374
Total operating expenses	54,452	36,566
Other Income (Expense):
Interest and other income, net	5,325	2,861
Interest expense	(398)	(364)
Total other income, net	4,927	2,497
Net Loss	$ (49,525)	$ (34,069)
Net loss per share, basic	$ (0.59)	$ (0.50)
Net loss per share, diluted	$ (0.59)	$ (0.50)
Weighted average number of shares used in computing net loss per share, basic	83,905	68,403
Weighted average number of shares used in computing net loss per share, diluted	83,905	68,403
Comprehensive Loss:
Net loss	$ (49,525)	$ (34,069)
Other comprehensive income:
Unrealized gain on marketable securities	455	2,136
Comprehensive Loss	$ (49,070)	$ (31,933)

KURA Balance Sheet

2024-03-31

Condensed Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 41,506	$ 37,318
Short-term investments	485,616	386,639
Prepaid expenses and other current assets	10,713	8,524
Total current assets	537,835	432,481
Property and equipment, net	1,709	1,859
Operating lease right-of-use assets	6,698	6,993
Other long-term assets	7,666	7,602
Total assets	553,908	448,935
Current liabilities:
Accounts payable and accrued expenses	30,903	33,757
Current operating lease liabilities	1,363	1,506
Total current liabilities	32,266	35,263
Long-term debt, net	9,376	9,332
Long-term operating lease liabilities	6,231	6,362
Other long-term liabilities	951	705
Total liabilities	48,824	51,662
Stockholders'equity:
Preferred stock, $0.0001 par value; 10,000 shares authorized; no shares issued and outstanding
Common stock, $0.0001 par value; 200,000 shares authorized; 76,181 and 74,350 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	8	7
Additional paid-in capital	1,276,856	1,119,976
Accumulated other comprehensive loss	(816)	(1,271)
Accumulated deficit	(770,964)	(721,439)
Total stockholders'equity	505,084	397,273
Total liabilities and stockholders'equity	$ 553,908	$ 448,935

About Kura Oncology Inc

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase for the treatment of solid tumors and hematologic indications. The company has a clinical collaboration with Novartis to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression or PIK3CA mutation and/or amplification. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.

CEO	Dr. Troy Edward Wilson J.D., Ph.D.
WEBSITE	https://kuraoncology.com
INDUSTRY	Biotechnology
EMPLOYEES	133

Kura Oncology Inc Frequently Asked Questions

What is the ticker symbol for Kura Oncology Inc? What does KURA stand for in stocks?

KURA is the stock ticker symbol of Kura Oncology Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Kura Oncology Inc (KURA)?

As of Mon May 13 2024, market cap of Kura Oncology Inc is 1.57 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of KURA stock?

You can check KURA's fair value in chart for subscribers.

What is the fair value of KURA stock?

You can check KURA's fair value in chart for subscribers. The fair value of Kura Oncology Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Kura Oncology Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for KURA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Kura Oncology Inc a good stock to buy?

The fair value guage provides a quick view whether KURA is over valued or under valued. Whether Kura Oncology Inc is cheap or expensive depends on the assumptions which impact Kura Oncology Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for KURA.

What is Kura Oncology Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon May 13 2024, KURA's PE ratio (Price to Earnings) is -9.35 and Price to Sales (PS) ratio is 106.75. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. KURA PE ratio will change depending on the future growth rate expectations of investors.